In a major milestone for Dartmouth and for the future of molecular guided cancer surgery, Dartmouth has gained FDA approval for a study that may give surgeons a new “guiding light” during cancer surgeries. The approval gives Dartmouth the go-ahead for the first study involving humans of a fluorescent agent for guiding tumor surgery. The agent, called ABY-029, binds to cancer cell receptors and highlights tumors during surgery. Production of ABY-029 was coordinated by Dartmouth’s Thayer School of Engineering and Geisel School of Medicine, with Academic-Industrial partners Affibody AB, LI-COR Biosciences, and the University of Alabama at Birmingham using NCI grant funding.
“Our approach will dramatically accelerate the paradigm shift towards molecular guided surgical oncology,” says Keith Paulsen, the Robert A. Pritzker Professor of Biomedical Engineering and scientific director of Dartmouth’s Center for Surgical Innovation.
Read the full story at http://news.dartmouth.edu/news/2016/10/dartmouth-wins-fda-approval-aid-guide-cancer-surgery